Enanta Pharmaceuticals Stock Performance
| ENTA Stock | USD 8.56 0.45 4.99% |
The firm shows a Beta (market volatility) of 0.67, which means possible diversification benefits within a given portfolio. As returns on the market increase, Enanta Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Enanta Pharmaceuticals is expected to be smaller as well. At this point, Enanta Pharmaceuticals has a negative expected return of -0.63%. Please make sure to confirm Enanta Pharmaceuticals' maximum drawdown, rate of daily change, and the relationship between the jensen alpha and kurtosis , to decide if Enanta Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enanta Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (9.62) | Five Day Return (9.76) | Year To Date Return (19.25) | Ten Year Return (83.04) | All Time Return (52.62) |
1 | Enanta Pharmaceuticals, Inc. Short Interest Up 5.7 percent in August - MarketBeat | 09/03/2024 |
2 | Investment Analysis - Stock Traders Daily | 09/18/2024 |
3 | Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial ... | 09/26/2024 |
4 | Enanta Pharmaceuticals Surges 5.6 percent Is This an Indication of Further Gains | 10/02/2024 |
5 | Disposition of 4299 shares by Scott Rottinghaus of Enanta Pharmaceuticals at 15.07 subject to Rule 16b-3 | 10/03/2024 |
6 | Acquisition by Gardiner Nathaniel S. of 9250 shares of Enanta Pharmaceuticals subject to Rule 16b-3 | 10/21/2024 |
7 | ElectroCore, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/13/2024 |
8 | ARMISTICE CAPITAL, LLC Adjusts Stake in Enanta Pharmaceuticals Inc | 11/15/2024 |
9 | Enanta Pharmaceuticals Reports Q4 Loss, Misses Revenue Estimates | 11/25/2024 |
| Begin Period Cash Flow | 48 M |
Enanta |
Enanta Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,302 in Enanta Pharmaceuticals on August 29, 2024 and sell it today you would lose (446.00) from holding Enanta Pharmaceuticals or give up 34.25% of portfolio value over 90 days. Enanta Pharmaceuticals is currently does not generate positive expected returns and assumes 2.6283% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Enanta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enanta Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enanta Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enanta Pharmaceuticals, and traders can use it to determine the average amount a Enanta Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2395
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENTA |
Estimated Market Risk
| 2.63 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enanta Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enanta Pharmaceuticals by adding Enanta Pharmaceuticals to a well-diversified portfolio.
Enanta Pharmaceuticals Fundamentals Growth
Enanta Stock prices reflect investors' perceptions of the future prospects and financial health of Enanta Pharmaceuticals, and Enanta Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enanta Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.60) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 18.38 M | ||||
| Shares Outstanding | 21.19 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 1.33 X | ||||
| Price To Sales | 2.65 X | ||||
| Revenue | 79.2 M | ||||
| Gross Profit | 86.16 M | ||||
| EBITDA | (123.48 M) | ||||
| Net Income | (133.82 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 26.51 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 7.03 X | ||||
| Cash Flow From Operations | (103.15 M) | ||||
| Earnings Per Share | (5.45) X | ||||
| Market Capitalization | 190.91 M | ||||
| Total Asset | 462.27 M | ||||
| Retained Earnings | (207 M) | ||||
| Working Capital | 360 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
About Enanta Pharmaceuticals Performance
By analyzing Enanta Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Enanta Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enanta Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enanta Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.32) | |
| Return On Capital Employed | (0.39) | (0.38) | |
| Return On Assets | (0.33) | (0.32) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about Enanta Pharmaceuticals performance evaluation
Checking the ongoing alerts about Enanta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enanta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enanta Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 79.2 M. Net Loss for the year was (133.82 M) with profit before overhead, payroll, taxes, and interest of 86.16 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (103.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enanta Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Enanta Pharmaceuticals Reports Q4 Loss, Misses Revenue Estimates |
- Analyzing Enanta Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enanta Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Enanta Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enanta Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enanta Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enanta Pharmaceuticals' stock. These opinions can provide insight into Enanta Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |